*For medical professionals only
Many research achievements of Chinese researchers will be unveiled on the 2024 AATS international stage.
The 104th Annual Meeting of the American Academy of Thoracic Surgery (AATS) kicked off on April 27, 2024 local time at the Metropolitan Convention Center in Toronto, Ontario, Canada. This year, Chinese thoracic surgeons have contributed more than 30 high-quality clinical studies related to the diagnosis and treatment of lung cancer. The results of the study will be presented in two formats: "poster presentation" and "oral presentation". On this occasion, the "medical community" presents the clinical results presented by Chinese scholars on April 27, 2024, the first day of the 2024 AATS, for the benefit of readers.
Swipe left and right to see more images
Oral presentation
1. Prof. Li Shuben: Preoperative Positioning Guided by Electromagnetic Navigation Bronchoscopy - A Better Choice for Localization of Unilateral Pulmonary Multiple Nodules (The First Affiliated Hospital of Guangzhou Medical University/National Center for Respiratory Medicine)
Preoperative localization of multiple nodules in the ipsilateral lung is essential for precise resection. This study aims to evaluate the efficacy and safety of electromagnetically navigated bronchoscopy (ENB)-guided dye labeling for localization of multiple nodules in the ipsilateral lung. The study found that ENB-guided dye labeling could achieve similar localization accuracy to CT-guided lung puncture in patients with multiple nodules in the ipsilateral lung, with a shorter localization time and no complications. ENB-guided dye labeling is a safe and effective method for preoperative localization of multiple nodules in the ipsilateral lung.
2. Dr. Yuechun Lin: Effect of low-dose prednisolone on perioperative pleural effusion after pulmonary resection (The First Affiliated Hospital of Guangzhou Medical University/National Center for Respiratory Medicine)
Surgical trauma and tissue damage during video-assisted thoracoscopic surgery (VATS) may cause an inflammatory response and pleural effusion. Drainage of pleural effusions after VATS is challenging, including pain, respiratory changes, and increased complications. The study found that oral low-dose prednisolone showed a clear benefit in reducing chest drainage after pneumonectomy. May be considered in patients with a low risk of lobectomy for postoperative pleural effusion to avoid the need for thoracic drainage.
3. Dr. Jun-Feng Liu: The relationship between the number of lymph nodes dissected and long-term survival in patients with stage IA mixed vitreous lung adenocarcinoma (The Fourth Hospital of Hebei Medical University)
Resection of intrapulmonary and mediastinal lymph nodes (N1 and N2) in non-small cell lung cancer is recommended in the NCCN guidelines, but there is no exact number requirement. This retrospective cohort study investigated the relationship between the number of lymph nodes dissected and the long-term survival of patients with clinical stage IA lung adenocarcinoma with mixed vitreous shadow lung adenocarcinoma and determined the optimal threshold for the number of lymph node dissections. The number of lymph node dissections was found to be associated with relapsed, disease-free survival (RFS) and overall survival (OS) in patients with clinical stage IA mixed vitreous lung adenocarcinoma, especially in patients with lymph node metastases. It is recommended that at least 12 lymph nodes be examined to assess the quality of the lymph node examination.
4. Dr. Xinyu Yang: Comparative study on recurrence mode and survival of neoadjuvant immunochemotherapy and neoadjuvant chemotherapy and radiotherapy in patients with locally advanced esophageal squamous cell carcinoma (Zhongshan Hospital, Fudan University)
Few studies have reported the prognosis of patients with locally advanced squamous cell carcinoma (LA-ESCC) receiving neoadjuvant immunochemotherapy (nICT). This study aims to evaluate the difference in recurrence and overall survival between nICT versus neoadjuvant chemotherapy radiotherapy (nCRT) for LA-ESCC. Neoadjuvant immunochemotherapy may provide better PFS and RFS benefits in patients with locally advanced squamous cell carcinoma. Further validation is needed in randomized controlled trials.
5. Prof. Yang Yang: Robot-assisted and traditional minimally invasive esophagectomy for the treatment of resectable esophageal squamous cell carcinoma (Shanghai Chest Hospital)
Minimally invasive esophagectomy (MIE) has become the standard treatment for esophageal cancer in most parts of the world. Robotic-assisted minimally invasive esophagectomy (RAMIE) compared to conventional thoracoscopic MIE has not been studied in randomized trials. We aimed to investigate whether RAMIE is no inferior to MIE in patients with resectable esophageal squamous cell carcinoma (ESCC). Robotic-assisted techniques have shown higher 3-year OS and DFS rates than MIE in ESCC patients receiving neoadjuvant therapy. These results should be confirmed in an independent superiority trial before RAMIE can be recommended as the preferred surgical option.
6. Dr. Wang Shuai: A New Classification of Thymoma-related Myasthenia Gravis and Its Clinical Relevance (Zhongshan Hospital, Fudan University)
There is heterogeneity in the treatment and outcomes of thymoma-associated myasthenia gravis (TAMG). Here, we propose a new classification system to shape treatment outcomes and stratification of TAMG. Taking into account oncological and neurological factors, the new classification system improves outcome stratification and provides valuable information for clinical decision-making in TAMG.
Another highlight of the first day was the application and prospect of the fifth-generation da Vinci robot in thoracic surgery. The fifth-generation robot with force feedback may once again open a new chapter in surgery!
Exciting information is waiting for you
* This article is only for the purpose of providing scientific information to medical professionals and does not represent the views of this platform